New Approaches to Therapy in PsA Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25. https://t.co/9vHgQ6S2JD https://t.co/5mvX1rOrIP

• https://buff.ly/k0PoO7n

Why I love the late breaking abstracts https://t.co/jCSfNOoFeT https://t.co/uZWSm9SQAI

• Why I love the late breaking abstracts | RheumNow

Tuesday Nite Rheumatology (on 11.11.25) https://t.co/xk8NOwLN7z

• Dr. John Cush

The Interview (11.7.2025) I've conducted thousands of interviews, mainly for medical school admissions and medical or research jobs. They're all similar, with me seeking the "right one" and interviewees feeling apprehensive, uncertain, and hopeful. My extensive experience has https://t.co/KZzfEKx4qm

Late-Breaking Trials in axSpA and PsA https://t.co/EWeF0nkb1h https://t.co/HgY0be0PDX

• Late-Breaking Trials in axSpA and PsA | RheumNow

Diagnostic Delays in PsA: A Radiographic Perspective Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25. https://t.co/iLllm7DcCF

S.Korean study of 481 pts w/ myositis (IIM) - 12.9% (n = 62) had myositis-assoc. cancer. CA risk factos= older age, male, current smoking, dermatomyositis, TIF1γ; but lower risk w/ anti-synthetase synd, overlap myositis, arthritis, & ILD. SCRIM score had AUROC = 0.852 https://t.co/MdU1fRWWgS

Genentech announced positive results from the phase III DBRPCT ALLEGORY trial showin safety & efficacy of obinutuzumab in ~300 SLE pts on SOC. Results have yet to be presented publicly. https://t.co/4hoT9dBtPq

• Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Di…

Tapering in SELECT GCA: Steroids are the Problem Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at #ACR25. https://t.co/80Bl49uImB https://t.co/GjlHHjPW2u

• https://buff.ly/Fr390Gx

Systematic review of 10 studies showed TNFi exposure in utero not assoc w/ incr risk of infant severe infxn (4 RCTs); same for breast milk exposure (2 RCTs). Infant vaccination outcomes unaffected by TNFi use, but rec delaying BCG vaccination if TNFi exposed https://t.co/02Nn6TuzR3

Combining CAR-T with CAR-Treg All in One Dr. Alfred Kim reports on abstract 0981 (GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases). https://t.co/SXuLYyUCXo https://t.co/5CAzoGfOyf

• https://buff.ly/fRSTpa5

Bone Density in Ankylosing Spondylitis At #ACR25, a retrospective study from China tackled this challenge using quantitative computed tomography (QCT), a more precise imaging modality that measures true volumetric bone density unaffected by cortical ossifications. https://t.co/1Z5cshkqjt

IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies. https://t.co/MyqCjilYGL

In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ https://t.co/AiK2K9whBH